Katherine A. Hicks

Katherine A. Hicks

Auto-generated profile, based on publicly available information

Katherine A. Hicks

RTI Health Solutions

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2005 in Annals of Internal Medicine
Verified
Journal Article
Closed access
WHWilliam H. Herman
William H. Herman
THThomas J. Hoerger
Thomas J. Hoerger
MBMichael Brandle
Michael Brandle
KHKatherine Hicks
Katherine Hicks
SSStephen Sorensen
Stephen Sorensen
FGfor the Diabetes Prevention Program Research Group*
for the Diabetes Prevention Program Research Group*
This cost-effectiveness analysis estimates that the Diabetes Prevention Program's lifestyle intervention would cost society about $8800 per quality-adjusted life-year saved. The corresponding resul... Background: The Diabetes Prevention Program (DPP) demonstrated that interventions can delay or prevent the development of type 2 diabetes. Objective: To estimate the lifetime cost–utility of the DP...

1 February 2001 in Journal of Marriage and Family
Verified
Journal Article
Closed access
PDF file
SESusan T. Ennett
Susan T. Ennett
KBKarl E. Bauman
Karl E. Bauman
VFVangie A. Foshee
Vangie A. Foshee
MPMichael Pemberton
Michael Pemberton
KHKatherine A. Hicks
Katherine A. Hicks

4 May 2004 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
THThomas J. Hoerger
Thomas J. Hoerger
RHRussell Harris
Russell Harris
KHKatherine A. Hicks
Katherine A. Hicks
KDKatrina Donahue
Katrina Donahue
SSStephen Sorensen
Stephen Sorensen
MEMichael Engelgau
Michael Engelgau
No randomized, controlled trial of screening for diabetes has been conducted. In the absence of direct evidence, cost-effectiveness models may provide guidance about preferred screening strategies. To estimate the incremental cost-effectiveness of 2 diabetes screening strategies: screening targeted to people with hypertension and universal screening. Markov model. United Kingdom Prospective Diabetes Study, Hypertension Optimal Treatment trial, and recent cost data. General primary care population in the United States. Lifetime. Health care system. Diabetes screening targeted to people with hypertension and universal screening. Cost per quality-adjusted life-year (QALY) gained. Costs (in 1997 U.S. dollars) and QALYs discounted at a 3% annual rate. At all ages, incremental cost-effectiveness ratios were more favorable for screening targeted to people with hypertension than for universal screening. For example, at age 55 years, the cost per QALY for targeted screening compared with no screening was $34 375, whereas the cost per QALY for universal screening compared with targeted screening was $360 966. Screening was more cost-effective for ages 55 to 75 years than for younger ages. In single-way and probabilistic sensitivity analyses, findings were robust to therapy costs, screening costs, screening lead time, reduced effectiveness of intensive antihypertensive therapy, and increased relative risk reduction for stroke attributable to intensive hypertension control. We did not consider screening targeted to persons with dyslipidemia, and we used studies of people whose diabetes was detected clinically to estimate screening benefits. Diabetes screening targeted to people with hypertension is more cost-effective than universal screening. The most cost-effective strategy is targeted screening at age 55 to 75 years.

1 November 2007 in Diabetes Care
Verified
Journal Article
Open access
PDF file
THThomas J. Hoerger
Thomas J. Hoerger
KHKatherine A. Hicks
Katherine A. Hicks
SSStephen W. Sorensen
Stephen W. Sorensen
WHWilliam H. Herman
William H. Herman
RRRobert E. Ratner
Robert E. Ratner
MEMichael M. Engelgau
Michael M. Engelgau
OBJECTIVE—To estimate the cost-effectiveness of screening overweight and obese individuals for pre-diabetes and then modifying their lifestyle based on the Diabetes Prevention Program (DPP).

1 August 2018 in Vaccine
Verified
Journal Article
Open access
DCD. Curran
D. Curran
BPB. Patterson
B. Patterson
LVL. Varghese
L. Varghese
DOD. Van Oorschot
D. Van Oorschot
PBPhilip Buck
Philip Buck
BYBarbara P Yawn
Barbara P Yawn
In the United States, herpes zoster (HZ) and related complications are estimated to result in approximately $1.3 billion in medical care costs and $1.7 billion in indirect costs annually. In this study, we compared the cost-effectiveness of a new Adjuvanted Recombinant Zoster Vaccine (RZV), containing recombinant varicella-zoster virus glycoprotein E and the AS01B Adjuvant System, versus No Vaccine, as well as versus the live attenuated HZ vaccine (Zoster Vaccine Live (ZVL)) in subjects aged 60+ years of age (YOA) and other age cohorts aged 50+ YOA. A multi-cohort Markov model was developed which follows 1 million individuals over their remaining lifetimes from the year of vaccination with annual cycle lengths. Second dose compliance for RZV was assumed to be 69%. Efficacy and waning parameters were derived from clinical trials for both vaccines. Epidemiological parameters, costs and utility model inputs were derived from US-specific population-based data. Costs and outcomes were discounted at 3% per year. Deterministic and probabilistic sensitivity analysis, along with scenario and threshold analysis were carried out to explore the overall uncertainty in the model. The model estimated that, compared to No Vaccine against HZ, RZV would prevent 103,603 HZ cases, 11,197 postherpetic neuralgia (PHN) cases, and 14,455 other complications, at an incremental cost of $11,863 per quality-adjusted life-year saved from a societal perspective. Compared to ZVL, the model estimated that, RZV would prevent 71,638 additional HZ cases, 6403 PHN cases, and over 10,582 other complications, resulting in net total societal cost savings of over $96 million. The results were robust to a wide range of sensitivity analyses. Vaccination against HZ with RZV is cost-effective compared to No Vaccine and cost-saving compared to ZVL, in the US population aged 60+ YOA. Clinicaltrial.gov. registered#: NA.

1 June 2006 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
RARonald T. Ackermann
Ronald T. Ackermann
DMDavid G. Marrero
David G. Marrero
KHKatherine A. Hicks
Katherine A. Hicks
THThomas J. Hoerger
Thomas J. Hoerger
SSStephen Sorensen
Stephen Sorensen
WHWilliam H. Herman
William H. Herman
OBJECTIVE—The Diabetes Prevention Program (DPP) lifestyle intervention is a cost-effective strategy to prevent type 2 diabetes, but it is unclear how this intervention could be financed. We explored whether this intervention could be offered in a way that allows return on investment for private health insurers while remaining attractive for consumers, employers, and Medicare. RESEARCH DESIGN AND METHODS—We used the DPP and other published reports to build a Markov simulation model to estimate the lifetime progression of disease, costs, and quality of life for adults with impaired glucose tolerance. The model assumed a health-payer perspective and compared DPP lifestyle and placebo interventions. Primary outcomes included cumulative incidence of diabetes, direct medical costs, quality-adjusted life-years (QALYs), and cost per QALY gained. RESULTS—Compared with placebo, providing the lifestyle intervention at age 50 years could prevent 37% of new cases of diabetes before age 65, at a cost of $1,288 per QALY gained. A private payer could reimburse $655 (24%) of the $2,715 in total discounted intervention costs during the first 3 intervention years and still recover all of these costs in the form of medical costs avoided. If Medicare paid up to $2,136 in intervention costs over the 15-year period before participants reached age 65, it could recover those costs in the form of future medical costs avoided beginning at age 65. CONCLUSIONS—Cost-sharing strategies to offer the DPP lifestyle intervention for eligible people between ages 50 and 64 could provide financial return on investment for private payers and long-term benefits for Medicare.